On Vaccines and Vaccinology, in COVID and Beyond
The a16z Show14 Aug 2020

On Vaccines and Vaccinology, in COVID and Beyond

WHEN are we going to have a COVID-19 vaccine, and how the heck are we going from (what’s been traditionally been up to) 12 years or so of vaccine development compressed into 12 months or so? What will and won’t be compromised here, and where do new technologies -- like mRNA or messenger RNA vaccines -- come in? Where will vaccines likely be distributed first, who will and won't get them initially, both across populations... and nations?

Rajeev Venkayya, president of the Global Vaccine Business Unit at Takeda Pharmaceutical Company and former White House Special Assistant to the President for Biodefense (where, among other things, he was the principal author of the National Strategy for Pandemic Influenza) joins this special deep-dive episode of the a16z Podcast, in conversation with general partner Jorge Conde to discuss all things vaccines. Including where does manufacturing and scale-up come in -- is "plug and play" really here? -- and by the way, why have we traditionally used eggs in growing vaccines?

Where and how can startups and others participate in vaccine development, given how competitive, time-consuming, capital intensive, and risky it is to develop (and sell) them? Can we decouple the question of how we reopen schools with when we have a vaccine? And how do we maintain not just safety and efficacy of vaccines but trust and transparency when it comes to mis/information? We may actually see the emergence of a "Neo Anti-Vaxxer" thanks to the rush... but we may also be entering a renaissance for vaccinology after this pandemic. So what changes, what doesn't?

image: Jernej Furman / Flickr

Stay Updated:

Find a16z on YouTube: YouTube

Find a16z on X

Find a16z on LinkedIn

Listen to the a16z Show on Spotify

Listen to the a16z Show on Apple Podcasts

Follow our host: https://twitter.com/eriktorenberg

Please note that the content here is for informational purposes only; should NOT be taken as legal, business, tax, or investment advice or be used to evaluate any investment or security; and is not directed at any investors or potential investors in any a16z fund. a16z and its affiliates may maintain investments in the companies discussed. For more details please see a16z.com/disclosures.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Episoder(1000)

2024 Big Ideas: Developer Influence, Maritime Upgrades, and New Video Intelligence

2024 Big Ideas: Developer Influence, Maritime Upgrades, and New Video Intelligence

A new age of maritime exploration, the rise of the developer as a buyer in financial services, and more applications for computer vision and video intelligence. We asked over 40 partners across a16z t...

22 Des 202347min

Text to Video: The Next Leap in AI Generation

Text to Video: The Next Leap in AI Generation

General Partner Anjney Midha explores the cutting-edge world of text-to-video AI with AI researchers Andreas Blattmann and Robin Rombach. Released in November, Stable Video Diffusion is their latest o...

20 Des 202332min

2024 Big Ideas: Voice-First Apps, AI Moats, Never-Ending Games, and Anime Takes Off

2024 Big Ideas: Voice-First Apps, AI Moats, Never-Ending Games, and Anime Takes Off

Voice-First Apps, AI Moats, Never-Ending Games, and Anime. We asked over 40 partners across a16z to preview one big idea they believe will drive innovation in 2024.Here in our 3-part series, you’ll he...

15 Des 20231h

Safety in Numbers: Keeping AI Open

Safety in Numbers: Keeping AI Open

Arthur Mensch is the co-founder of Mistral and the co-author of Deepmind’s pivotal 2022 "Chinchilla" paper.In September 2023, Mistral released Mistral-7B, an advanced open-source language model that h...

11 Des 202334min

2024 Big Ideas: Miracle Drugs, Programmable Medicine, and AI Interpretability

2024 Big Ideas: Miracle Drugs, Programmable Medicine, and AI Interpretability

Smart energy grids. Voice-first companion apps. Programmable medicines. AI tools for kids.
We asked over 40 partners across a16z to preview one big ideathey believe will drive innovation in 2024.Here ...

8 Des 20231h 5min

The Quest for AGI: Q*, Self-Play, and Synthetic Data

The Quest for AGI: Q*, Self-Play, and Synthetic Data

One topic at the center of the AI universe this week is a potential breakthrough called Q*. Little has been revealed about this OpenAI project, other than its likely relationship to solving certain gr...

4 Des 202326min

Financial Freedom, Company Building, More with David Marcus

Financial Freedom, Company Building, More with David Marcus

with @davidmarcus @smc90This wide-ranging conversation covers company building, big to small -- including what cadence and when is the right "time" to ship; the relationship between centralization, de...

28 Nov 202348min

When Business is Battle: Inside the Boardrooms of the CEOs that Survived the Storm

When Business is Battle: Inside the Boardrooms of the CEOs that Survived the Storm

Taking a company from idea to household name is always difficult. But the past few years presented challenges that caught even the most-seasoned CEOs off guard.In this episode, you’ll hear from two CE...

23 Nov 202351min

Populært innen Business og økonomi

stopp-verden
lydartikler-fra-aftenposten
dine-penger-pengeradet
e24-podden
rss-penger-polser-og-politikk
rss-borsmorgen-okonominyhetene
finansredaksjonen
pengepodden-2
pengesnakk
livet-pa-veien-med-jan-erik-larssen
tid-er-penger-en-podcast-med-peter-warren
rss-sunn-okonomi
morgenkaffen-med-finansavisen
utbytte
stormkast-med-valebrokk-stordalen
lederpodden
rss-markedspuls-2
liberal-halvtime
rss-politisk-preik
okonomiamatorene